Is RVTY a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Revvity (RVTY) rests on Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics: Diagnostics revenue reached ~$371.0 million in the quarter ended July 5, 2026, up from ~$354.4 million a year earlier, and grew 12% on a pro forma basis with 11% pro forma organic growth. The bear case rests on the most immediate risk is that a chunk of 2026 profit does not repeat. Analysts covering it publish targets from $122.00 to $200.00 against a $145.22 share price on November 20, 2026, so even the professionals disagree by 46% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
RVTY key stats
At $145.22 on November 20, 2026, Revvity (RVTY) has a market cap of $16.2B, a P/E of 64.5 on trailing earnings (24.4 on forward earnings) and a dividend yield of 0.19%. It next reports earnings around February 1, 2027 (estimated).
- Market cap
- $16.2B
- P/E (trailing)
- 64.5
- P/E (forward)
- 24.4
- EPS (trailing 12 months)
- $2.25
- Price to book
- 2.2
- Dividend yield
- 0.19%
- Beta
- 1.09
- Next earnings
- around February 1, 2027 (estimated)
Market cap, P/E and yield are measured at the $145.22 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Revvity (RVTY)?
The last two weeks for Revvity, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- RVTY closed at $145.22 on November 20, 2026, down 5.9% over the past five trading days (from $154.39).
- Revvity next reports quarterly results around February 1, 2027 (estimated).
- On November 13, 2026, Revvity filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
- On November 10, 2026, Revvity filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 16, 2026, JP Morgan raised its target to $165.00 from $160.00 (Neutral).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Revvity runs two reporting segments of nearly identical size. Life Sciences sold ~$720.5 million in the first half of fiscal 2026 and covers two product lines: Life Sciences Solutions (~$601.0 million), meaning reagents, assays, labeling and detection chemistry, automation and high-content imaging systems such as the Opera Phenix platform, and Signals software (~$119.5 million), a scientific informatics suite sold on subscription to pharmaceutical R&D organizations. Diagnostics sold ~$720.3 million over the same period and also splits two ways: immunodiagnostics (~$416.6 million), largely the EUROIMMUN autoimmune, allergy and infectious-disease immunoassay franchise, and reproductive health (~$303.7 million), which is newborn screening, prenatal testing and related genomic services. Customers are pharmaceutical and biotech R&D groups, clinical and public-health laboratories, academia and governments across more than 160 countries, served by roughly 11,000 employees. Geography is spread wide rather than concentrated: in the June quarter the Americas produced ~$325.6 million, Europe ~$229.0 million and Asia ~$175.1 million. A large share of revenue is consumable or subscription in nature, since assays, reagents and screening kits get bought again every period, while instruments and software licenses carry the cyclical part of the business. The investment picture turns on three things: whether Diagnostics keeps compounding, whether pharma instrument and software spending recovers, and how much of the GAAP earnings gap an owner is willing to look through. Revenue has been close to flat over three fiscal years, ~$2.751 billion in 2023, ~$2.755 billion in 2024 and ~$2.856 billion in 2025, so the equity story has been margin, buybacks and mix rather than volume. Adjusted operating margin ran 28.9% in the June quarter against a GAAP operating margin of 12.2%, and the wedge between them is ~$84.9 million of quarterly intangible amortization sitting on ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles, the accounting residue of the acquisition spree that built EUROIMMUN, BioLegend and the Signals portfolio. Management raised full-year guidance on August 4, 2026 to 4% to 5% pro forma organic growth and $5.30 to $5.40 of pro forma adjusted EPS. Guidance is now stated excluding the China immunodiagnostics business, which is under a signed agreement to be sold, so the guided revenue base and the reported revenue base are no longer the same thing. The third quarter kept the pattern of small beats. For the quarter ended October 4, 2026, revenue was ~$709.6 million, up about 4.3% year over year and above the ~$695 million consensus, adjusted EPS was $1.37 against an estimate of $1.30, and GAAP net income was ~$62.3 million. That makes four straight quarters of adjusted EPS ahead of estimates. The share price has cooled since the October peak: RVTY closed at about $145.23 on November 20, 2026, down about 8.5% over the past month but up about 16% over three months and about 48% year to date, after touching a 52-week high of about $171.74. Analysts kept lifting targets after the report, with Barclays moving to $175 from $160 on November 4, and the mean target of about $171.40 across 15 analysts now sits above the share price with a consensus buy rating. Revvity held a 2026 Investor Day on November 13 under the theme "Powering Scientific Intelligence" to present its long-range outlook. The next report, for the fourth quarter, is expected around February 1, 2027, with consensus at about $1.62 of adjusted EPS on about $762 million of revenue.
The bull case: what would have to be true for $200.00
The most optimistic published target on RVTY is $200.00, +37.7% from the $145.22 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics
Diagnostics revenue reached ~$371.0 million in the quarter ended July 5, 2026, up from ~$354.4 million a year earlier, and grew 12% on a pro forma basis with 11% pro forma organic growth. Reproductive health was the strongest line at ~$156.2 million against ~$135.6 million, a gain of ~15%, helped by newborn screening volumes and a Genomics England sequencing contract that management sized at roughly $25 million for full-year 2026 on the August earnings call. Segment adjusted operating income rose to ~$112.9 million from ~$89.4 million, taking margin from 25.2% to 30.4%, an improvement of 520 basis points that the 10-Q attributes to tariff refunds and cost containment. For the half, Diagnostics adjusted operating income was ~$189.0 million on ~$720.3 million of revenue.
2. The China immunodiagnostics exit resets the base
On July 31, 2026 Revvity signed a definitive agreement to divest its immunodiagnostics business in China, disclosed in the 10-Q as roughly 6% of fiscal 2025 revenue, with closing expected by the end of 2027 subject to regulatory approval. Chief executive Prahlad Singh described China as a structurally more difficult environment for that unit. The immediate effect is presentational and material: forward guidance is given only on a pro forma basis that strips the unit out, so full-year 2026 pro forma revenue of $2.83 to $2.86 billion sits below the ~$2.91 billion the company actually collected over the twelve months to July 5, 2026 (~$2.94 billion through October 4). Immunodiagnostics outside China grew high single digits in the quarter even with tuberculosis testing pressure in the Americas. Asia revenue fell to ~$175.1 million from ~$193.1 million year over year.
3. Software is the swing factor inside Life Sciences
Signals software revenue was ~$57.7 million in the June quarter against ~$67.8 million a year earlier, a decline of roughly 15% as reported and about 20% organically, which management attributed to a hard comparison and contract timing rather than lost accounts. Annual platform value continues to grow at a double-digit rate by the company's account, and management guided to a return to double-digit software growth in the second half. Revvity bought Advanced Chemistry Development (ACD/Labs) of Toronto in the first quarter of 2026 for $72.0 million in cash plus up to $8.0 million of contingent consideration, adding analytical characterization and molecular design software to the segment. A Signals AI release with an Anthropic Claude connector went out during the quarter. Life Sciences overall fell 3% organically, with reagents roughly flat at ~$301.0 million.
4. Share count is shrinking and the balance sheet is getting lighter
Revvity spent ~$820.8 million on buybacks in fiscal 2025 and another ~$102.5 million in the first half of 2026. Weighted average diluted shares fell to ~111.7 million for the six months ended July 5, 2026 from ~118.9 million a year earlier, a reduction of about 6%, which is why adjusted EPS grows faster than adjusted operating income. In July 2026 the company repaid its EUR 500.0 million 1.875% senior notes at maturity for ~$571.2 million in cash, which retired the only near-term maturity and left ~$2.65 billion of principal running out to 2028 through 2051. Management put net leverage at approaching 2x on the call. Operating cash flow from continuing operations was ~$317.8 million in the half against ~$268.4 million, with capital expenditure of only ~$30.8 million.
The bear case: what would have to be true for $122.00
The most pessimistic published target is $122.00, -16.0% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Revvity is worth if the risks below bite instead of the drivers above.
The most immediate risk is that a chunk of 2026 profit does not repeat. Following the Supreme Court's February 20, 2026 ruling that the International Emergency Economic Powers Act does not authorize tariffs, Revvity applied through the Customs and Border Protection refund process for $20.2 million and had received $16.2 million by July 5, 2026. The company books these on receipt and has recorded no refund receivable, and the full $16.2 million landed in cost of revenue in a single quarter, worth roughly $0.11 of the $1.41 adjusted EPS and a good part of the 260 basis points of gross margin expansion. Second, the end market has not fully turned. Pharma and biotech sales declined mid-single digits including software in the quarter, academic and government budgets remain unsettled, and instruments are a deferrable purchase when customers are cautious. Third, the China divestiture is signed but not closed, with completion expected only by the end of 2027 and conditioned on regulatory approval, so Revvity carries the unit's declining results in the meantime while guiding without it. Fourth, the balance sheet is intangible-heavy: ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles against ~$12.05 billion of total assets and ~$7.23 billion of equity, which leaves real impairment exposure if any acquired franchise underperforms. Fifth, restructuring is ongoing and disruptive, with severance actions in the first half of 2026 touching roughly 5% of the workforce and ~$46.2 million of charges recorded. Sixth, reproductive health revenue is tied to birth rates and to public-health screening budgets, both outside the company's control, and tuberculosis testing in the Americas is already a stated drag. Debt is ~$2.65 billion after the July repayment, with interest expense of ~$47.7 million in the half. Finally, after a roughly 48% gain in 2026 the stock trades near $145 and at about 24 times expected 2027 earnings, a premium to its own history that leaves little room for a guidance miss, and the shares already fell about 8.5% in the month to November 20 despite a third-quarter beat. Reported revenue growth was only about 4.3% in that quarter, so most of the earnings growth still has to come from margin and share count.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding RVTY already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on RVTY
15 analysts cover RVTY, with an average target of $171.40 (+18.0% against $145.22) and a split of 6 buy, 11 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the RVTY forecast and price target page.
How is RVTY valued?
Market cap, P/E and dividend yield at today's price are in the RVTY key stats above. The business figures below come from Revvity's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$2.94 billion for the twelve months to October 4, 2026, with third-quarter revenue of ~$709.6 million up about 4.3% year over year and above the ~$695 million consensus. Growth has been slow rather than absent: ~$2.751 billion in fiscal 2023, ~$2.755 billion in fiscal 2024 and ~$2.856 billion in fiscal 2025. Analysts expect ~$2.87 billion for fiscal 2026 and ~$3.04 billion for 2027. Note that fiscal 2026 ends January 3, 2027 and contains 53 weeks, one more than fiscal 2025.
- GAAP earnings versus adjusted earnings: Trailing twelve-month net income is ~$253 million and trailing diluted EPS ~$2.25, against $2.07 for full-year 2025 and $2.20 for 2024. Adjusted EPS was $1.37 in the September quarter against a $1.30 estimate, after $1.41 against $1.22 in the June quarter and $1.06 against $1.01 in the March quarter. In the June quarter the bridge was $0.76 of intangible amortization, $0.32 of restructuring, $0.05 of investment mark-to-market and $0.02 of purchase accounting, less $0.21 of tax. Consensus adjusted EPS is ~$5.44 for 2026 and ~$5.96 for 2027; in August management had guided 2026 pro forma adjusted EPS to $5.30 to $5.40.
- Margins: On Yahoo Finance's trailing basis, gross margin is ~55.9%, GAAP operating margin ~16.7% and net margin ~8.6%. Adjusted operating margin ran 28.9% in the June quarter against a GAAP operating margin of 12.2%, the gap being intangible amortization from past acquisitions.
- Segment and product-line mix: First-half 2026 revenue splits almost evenly, Life Sciences ~$720.5 million and Diagnostics ~$720.3 million. Within Life Sciences: Life Sciences Solutions ~$601.0 million and Signals software ~$119.5 million. Within Diagnostics: immunodiagnostics ~$416.6 million and reproductive health ~$303.7 million. Segment adjusted operating margins in the June quarter were 31.1% for Life Sciences (down from 31.6%) and 30.4% for Diagnostics (up from 25.2%).
- Cash flow and balance sheet: Trailing operating cash flow is ~$656 million and free cash flow ~$633 million on Yahoo Finance's basis, against ~$589.0 million of operating cash flow for full-year 2025. Cash stood at ~$593 million at October 4, 2026 against ~$2.77 billion of total debt, after the EUR 500.0 million 1.875% notes were repaid at maturity in July for ~$571.2 million. Remaining notes mature in 2028, 2029, two 2031 tranches and 2051, plus a $1.5 billion revolver running to January 2030. Goodwill was ~$6.61 billion and net intangibles ~$2.22 billion at July 5, 2026.
- Market pricing: The shares closed at ~$145.23 on November 20, 2026 against a 52-week range of ~$81.22 to ~$171.74, giving a market capitalization of ~$16.2 billion. Trailing GAAP P/E is ~65x on ~$2.25 of trailing EPS; against ~$5.44 of 2026 consensus adjusted EPS the multiple is ~27x, and against the ~$5.96 analysts expect for 2027 it is ~24x. Price-to-sales is ~5.5x on trailing revenue, and EV/EBITDA is ~21x. The analyst mean target is ~$171.40 across 15 analysts.
- Dividend and buyback: The quarterly dividend is $0.07 a share, $0.28 annualized, for a yield of roughly 0.18% at the November 20, 2026 price and a payout of about 12% of trailing GAAP earnings. Repurchases do the heavy lifting instead: ~$820.8 million in fiscal 2025 and ~$102.5 million in the first half of 2026, cutting weighted average diluted shares to ~111.7 million from ~118.9 million year over year.
As of November 2026: The multiple depends entirely on which earnings line an owner treats as economic. A trailing GAAP P/E near 65x reflects ~$340 million a year of amortization on intangibles Revvity paid cash for in prior years; a multiple near 27x on 2026 consensus adjusted EPS, or about 24x on 2027 consensus, treats that amortization as sunk. After a roughly 48% gain in 2026 the stock carries a premium closer to faster-compounding life-science tools names than to slow-growth diagnostics, while reported revenue grew only about 4.3% in the third quarter. The fourth-quarter report, expected around February 1, 2027, is the next test of whether margin, buybacks and the instrument backlog can carry that premium.
How do you decide if RVTY is a buy?
Whether RVTY is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold RVTY indirectly through an index or sector ETF before adding more.
What would change your mind on RVTY
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the most immediate risk is that a chunk of 2026 profit does not repeat fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the RVTY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RVTY against your real portfolio and see your actual exposure before deciding.
Your questions about Revvity
Ask Walnut's AI anything about RVTY and see how it fits what you own.
FAQ
Is RVTY a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics, with revenue (ttm) at ~$2.94 billion for the twelve months to October 4, 2026, with third-quarter revenue of ~$709.6 million up about 4.3% year over year and above the ~$695 million consensus. Growth has been slow rather than absent: ~$2.751 billion in fiscal 2023, ~$2.755 billion in fiscal 2024 and ~$2.856 billion in fiscal 2025. Analysts expect ~$2.87 billion for fiscal 2026 and ~$3.04 billion for 2027. Note that fiscal 2026 ends January 3, 2027 and contains 53 weeks, one more than fiscal 2025.. The bear case rests on the most immediate risk is that a chunk of 2026 profit does not repeat. Analysts covering it are spread from $122.00 to $200.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell RVTY?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The most immediate risk is that a chunk of 2026 profit does not repeat. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $122.00, -16.0% from the $145.22 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for RVTY?
+
Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics. Diagnostics revenue reached ~$371.0 million in the quarter ended July 5, 2026, up from ~$354.4 million a year earlier, and grew 12% on a pro forma basis with 11% pro forma organic growth. The most optimistic analyst target on RVTY is $200.00, +37.7% from the $145.22 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for RVTY?
+
The most immediate risk is that a chunk of 2026 profit does not repeat. Following the Supreme Court's February 20, 2026 ruling that the International Emergency Economic Powers Act does not authorize tariffs, Revvity applied through the Customs and Border Protection refund process for $20.2 million and had received $16.2 million by July 5, 2026. The company books these on receipt and has recorded no refund receivable, and the full $16.2 million landed in cost of revenue in a single quarter, worth roughly $0.11 of the $1.41 adjusted EPS and a good part of the 260 basis points of gross margin expansion. Second, the end market has not fully turned. Pharma and biotech sales declined mid-single digits including software in the quarter, academic and government budgets remain unsettled, and instruments are a deferrable purchase when customers are cautious. Third, the China divestiture is signed but not closed, with completion expected only by the end of 2027 and conditioned on regulatory approval, so Revvity carries the unit's declining results in the meantime while guiding without it. Fourth, the balance sheet is intangible-heavy: ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles against ~$12.05 billion of total assets and ~$7.23 billion of equity, which leaves real impairment exposure if any acquired franchise underperforms. Fifth, restructuring is ongoing and disruptive, with severance actions in the first half of 2026 touching roughly 5% of the workforce and ~$46.2 million of charges recorded. Sixth, reproductive health revenue is tied to birth rates and to public-health screening budgets, both outside the company's control, and tuberculosis testing in the Americas is already a stated drag. Debt is ~$2.65 billion after the July repayment, with interest expense of ~$47.7 million in the half. Finally, after a roughly 48% gain in 2026 the stock trades near $145 and at about 24 times expected 2027 earnings, a premium to its own history that leaves little room for a guidance miss, and the shares already fell about 8.5% in the month to November 20 despite a third-quarter beat. Reported revenue growth was only about 4.3% in that quarter, so most of the earnings growth still has to come from margin and share count. The most pessimistic published target is $122.00, -16.0% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Revvity do?
+
Revvity is the life-sciences and diagnostics company left after PerkinElmer sold its analytical-instruments business in 2023.
What would have to change for RVTY to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the most immediate risk is that a chunk of 2026 profit does not repeat) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Revvity do?
+
Revvity sells the reagents, instruments, software and diagnostic tests used in life-science research and in clinical laboratories. Two segments of nearly equal size do the work. Life Sciences (~$720.5 million in the first half of fiscal 2026) supplies detection chemistry, labeling reagents, automation, high-content imaging systems and the Signals informatics suite to pharmaceutical and biotech R&D groups. Diagnostics (~$720.3 million) supplies EUROIMMUN immunoassays for autoimmune, allergy and infectious disease testing, plus newborn and prenatal screening products used by public-health programs. About 11,000 employees serve customers in more than 160 countries, and the company has been a member of the S&P 500 through the transition. Much of the revenue is consumable or subscription based, since assays and screening kits are reordered continuously.
Is Revvity the same company as PerkinElmer?
+
Same SEC registrant, different business. The legal entity is CIK 0000031791, which filed as EG&G, then as PerkinElmer, and now as Revvity, Inc. In March 2023 it sold the Applied, Food and Enterprise Services businesses (the analytical instruments side) to funds managed by New Mountain Capital for approximately $2.136 billion at closing, and the agreement transferred the PerkinElmer brand and trademarks to the buyer as well, with $75 million of deferred payments tied to it. A separate private company now trades on the PerkinElmer name. Anything written about PerkinElmer's chromatography, spectroscopy or food-safety instrument lines describes a business Revvity no longer owns. EDGAR still classifies the registrant under SIC 3826, Laboratory Analytical Instruments, which is a leftover code rather than a description.
Why is RVTY's P/E ratio so high?
+
Trailing GAAP earnings are ~$253 million, or ~$2.25 a diluted share for the twelve months to October 4, 2026, which against a ~$145.23 share price on November 20, 2026 gives a P/E near 65. The number is depressed by amortization of intangible assets, which ran ~$84.9 million in the June quarter alone, or $0.76 a share, and ~$170.0 million for the first half. Those charges are the accounting tail of past acquisitions such as EUROIMMUN and BioLegend, carried as ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles. Add back amortization, restructuring and a few smaller items and adjusted EPS was $1.37 in the September quarter, with analysts expecting ~$5.44 for full-year 2026. On that basis the multiple is roughly 27x on 2026 consensus and about 24x on the ~$5.96 analysts expect for 2027. Both numbers are real; they measure different things.
Walnut is informational, not investment advice, and gives no verdict on RVTY. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.